$39.27 -1.77 (-4.44%)

Mineralys Therapeutics, Inc. Common Stock (MLYS)

Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. The company utilizes proprietary technology to develop targeted treatments aimed at addressing unmet medical needs, with a particular emphasis on hyperkalemia. Mineralys aims to advance innovative solutions to improve patient outcomes in these therapeutic areas.

🚫 Mineralys Therapeutics, Inc. Common Stock does not pay dividends

Company News

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
The Motley Fool • Cory Renauer • September 7, 2025

Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
GlobeNewswire Inc. • Mineralys Therapeutics • September 5, 2025

Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga • Avi Kapoor • February 8, 2024

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 million. Compass Minerals International shares fell 9% to $20.52 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Syra Health Corp. (NASDAQ: SYRA) shares jumped 310% to $4.71 after the company announced a partnership for a federal contract valued at $75 billion. Hitek Global Inc. (NASDAQ: HKIT) surged 305% to $4.6220 after jumping more than 60% on Wednesday. MicroAlgo Inc. (NASDAQ: MLGO) shares climbed 160% to $1.48. CCSC Technology International Holdings Limited (NASDAQ: CCTG) shares gained 90.3% to $4.9299 after falling 20% on Wednesday. U Power Limited (NASDAQ: UCAR) climbed 75% to $0.1153. The company appointed Jean Christophe von Pfetten as an independent director and a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, effective February 1, 2024. WiMi Hologram Cloud Inc. (NASDAQ: WIMI) shares rose 53.3% to $1.2290 after gaining over 26% on Wednesday. Bit Brother Limited (NASDAQ: BETS) shares climbed 51.2% to $2.69 amid strength in Bitcoin. Arm Holdings plc (NASDAQ: ARM) shares climbed 47.3% to $113.41 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates. Zhongchao Inc. (NASDAQ: ZCMD) rose 41.5% to $0.4250. WeTrade Group, Inc. (NASDAQ: WETG) gained 38.6% to $3.05. Meiwu Technology Company Limited (NASDAQ: WNW) jumped 37% to $1.6205. Healthcare Triangle, Inc. (NASDAQ: HCTI) surged 36% to $3.8250. Oscar Health, Inc. (NYSE: OSCR) shares rose 21.2% to $16.27 after the company reported better-than-expected fourth-quarter financial results. Roma Green Finance Limited (NASDAQ: ROMA) shares gained 20.4% to $0.94 after declining over 5% on Wednesday. Mineralys Therapeutics, Inc. (NASDAQ: MLYS) surged 18.5% to $14.77. Mineralys Therapeutics announced ...

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
Zacks Investment Research • Zacks Equity Research • January 17, 2024

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strong Small-Cap Insider Buys: Q1 2023
Seeking Alpha • Quiver Quantitative • April 26, 2023

After the Q1 installment covering large-cap and mid-cap insider activity, we focus on the small-cap range. See the small-cap stocks we consider research-worthy.